Neurizon Therapeutics Ltd. Registered Shares o.N.
- BID
0.035
- ASK
0.048
- 50,000 Units41,667 Units
- 07/23, 15:49:28 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
56.59%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.02 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 0.035 G | 0 Units |
| PRICE DETERMINATION TIME | 07/23/2026 / 03:49:28 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 0.037 | 0.035 |
| PREV. DAY'S PRICE | 0.035 | (07/22) |
| CHANGE DAY BEFORE | +0.00 | 0.00 % |
| 52 WEEK HIGH / LOW | 0.0959 (08/08) | 0.027 (06/05) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.01 | -0.01 | -0.02 | - | - |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 6.70 | 8.48 | 27.94 | - | - |
PRICE - SALES RATIO | 8.53 | - | - | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A40STF |
| ISIN | AU0000357261 |
| SYMBOL | ECQ0 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Pharmaust |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.00 % | 0.00 % | -18.60 % | -10.26 % | -56.59 % | - | - | -19.54 % |
| HIGH | 0.04 | 0.04 | 0.06 | 0.07 | 0.10 | - | - | 0.07 |
| LOW | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | - | - | 0.03 |
Dividende
pro Aktie
Pharmaust does not deliver dividend information
Company profile
Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. It operates under the Corporate and Research, and Pharmaceutical-Epichem segments. The Corporate and Research segment includes corporate overhead expenses. The Pharmaceutical-Epichem segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.